Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Xeris Biopharma (XERS) reported $60.1 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 35.4%. EPS of -$0.03 for the same period compares to -$0.10 a year ago.The reported revenue represents a surprise of -0.81% over the Zacks Consensus Estimate of $60.59 million. With the consensus EPS estimate being -$0.07, the EPS surprise was +57.14%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Revenue- Gvoke: $23.26 million compared to the $23.90 million average estimate based on five analysts. Product Revenue- Keveyis: $11.12 million compared to the $21.19 million average estimate based on five analysts. Revenue- Royalty, contract and other: $3.10 million versus the five-analyst average estimate of $1.30 million. Revenue- Product revenue, net: $57 million versus $56.26 million estimated by five analysts on average. Product Revenue- Recorlev: $22.61 million versus $11.19 million estimated by five analysts on average. View all Key Company Metrics for Xeris Biopharma here>>>Shares of Xeris Biopharma have returned +2.7% over the past month versus the Zacks S&P 500 composite's -3.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Xeris Biopharma Holdings, Inc. (XERS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks